

**Product Name:** Depakene Coated Tablets  
**Issued:** Jun-01-2015



## **SAFETY DATA SHEET**

### **Section 1. Identification of the substance/mixture and of the company/undertaking**

#### **1.1 Product Identifier**

**Product Name:** Depakene Coated Tablets  
**Synonyms:** Sodium Valproate Coated Tablets; Depakote Tablets  
**List Number:** D925; E509

#### **1.2 Relevant identified uses of the substance or mixture and uses advised against**

**Recommended use:** Pharmaceuticals

#### **1.3 Details of the supplier of the safety data sheet**

**Supplier:** AbbVie Inc.  
1 North Waukegan Road  
North Chicago, IL 60064  
USA  
+1-847-932-7900  
**Customer Service Telephone:** 1-800-255-5162 (US and Canada only)  
+1-847-937-7433  
**E-mail Address:** AbbVie.SDS@abbvie.com

#### **1.4 Emergency telephone number**

**Emergency Telephone:** CHEMTREC: 1(800) 424-9300 (in USA and Canada)  
or +1-703-527-3887 (international)

### **Section 2. Hazards identification**

#### **2.1 Classification of the substance or mixture**

**Regulation (EC) No 1272/2008**

**General Note** AbbVie

**Acute oral toxicity** Category 4  
**Skin corrosion/irritation** Category 2  
**Serious eye damage/eye irritation** Category 2  
**Reproductive toxicity** Category 1A

**Classification according to EU Directives 67/548/EEC or 1999/45/EC**

**Indication of danger:** Xn - Harmful  
Xi - Irritant

**Product Name:**  
**Issued:**

**Depakene Coated Tablets**  
**Jun-01-2015**

**Risk Phrases:**

R22 - Harmful if swallowed  
R36/38 - Irritating to eyes and skin  
R61 - May cause harm to the unborn child  
R62 - Possible risk of impaired fertility

**2.2 Label elements**



**Signal Word:**

Danger

**Hazard Statements:**

H302 - Harmful if swallowed  
H315 - Causes skin irritation  
H319 - Causes serious eye irritation  
H360 - May damage fertility or the unborn child

**Precautionary Statements**

P301 + P312 - IF SWALLOWED: Call a POISON CENTER or doctor/physician if you feel unwell  
P302 + P352 - IF ON SKIN: Wash with plenty of soap and water  
P305 + P351 + P338 - IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing  
P202 - Do not handle until all safety precautions have been read and understood  
P281 - Use personal protective equipment as required  
P308 + P313 - IF exposed or concerned: Get medical advice/attention

**2.3 Other hazards**

Not determined

**Section 3. Composition/information on ingredients**

Chemical Name	Percent	EINECS/ELINCS Number	EEC Classification	EU - GHS Substance Classification	REACH No.
Sodium Hydrogen Divalproate 76584-70-8	50-70	NA	Xn, R22; Xi, R36/38; R61	Skin Irrit. 2 (H315) Eye Irrit. 2 (H319)	No data available
Talc, Nonasbestos Containing 14807-96-6	5-20	Present		Not Hazardous*	No data available
Silica, Amorphous 112926-00-8	1-10	NA		Not Hazardous*	No data available
Cellulose Microcrystalline 9004-34-6	1-10	Present		Not Hazardous*	No data available
Cellacefate 9004-38-0	1-10	NA		Not classified	No data available
Kollidon 9003-39-8	1-10	NA		Not Hazardous*	No data available

**Product Name:** Depakene Coated Tablets  
**Issued:** Jun-01-2015

Dibutyl Phthalate 84-74-2	1-10	Present	N; R50 Repr.Cat.2; R61 Repr.Cat.3; R62	Aquatic Acute 1 (H400) Repr. 1B (H360Df)	No data available
Titanium Dioxide 13463-67-7	0.1-1	Present		Not Hazardous*	No data available

Not Hazardous\* - Based on available data, not classified as hazardous according to the criteria of the Globally Harmonized System.

**For the full text of the R-phrases mentioned in this Section, see Section 16**  
**For the full text of the H-Statements mentioned in this Section, see Section 16**

## Section 4. First aid measures

### 4.1 Description of first aid measures

**Eye Contact:** Remove from source of exposure. Flush with copious amounts of water. If irritation persists or signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.

**Skin Contact:** Remove from source of exposure. Flush with copious amounts of water. If irritation persists or signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.

**Inhalation:** Remove from source of exposure. If signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.

**Ingestion:** Remove from source of exposure. If signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.

**Protection of First-aiders:** Use personal protective equipment

### 4.2 Most important symptoms and effects, both acute and delayed

**Signs and Symptoms:** None known from occupational exposure. Clinical data suggests the following: gastrointestinal upset, headaches, sedation, nausea, dizziness, hair loss, skin irritation, psychiatric changes, muscle weakness, thrombocytopenia, leucopenia, anemia, abnormal liver function. Clinical overdose may result in the following: coma.

**Medical Conditions Aggravated by Exposure:** None known from occupational exposure. Data suggest any pre-existing ailments in the following organs: liver. Current use of treatments such as: phenobarbital therapy. Hypersensitivity to the material and/or similar materials.

### 4.3 Indication of any immediate medical attention and special treatment needed

**Notes To Physician:** Naloxone has been reported to reverse the CNS depressant effects. Monitor liver function.

## Section 5. Firefighting measures

### 5.1 Extinguishing Media

**Suitable Extinguishing Media:** Use extinguishing agent suitable for type of surrounding fire

**Unsuitable Extinguishing Media:** Not determined

**Product Name:** Depakene Coated Tablets  
**Issued:** Jun-01-2015

## **5.2 Special hazards arising from the substance or mixture**

**Special Exposure Hazards:** Not determined

## **5.3 Advice for firefighters**

**Protective Equipment and Precautions for Firefighters:** As in any fire, wear self-contained breathing apparatus and full protective gear

# **Section 6. Accidental release measures**

## **6.1. Personal precautions, protective equipment and emergency procedures**

**Personal Precautions:** For personal protection see section 8.

## **6.2. Environmental precautions**

**Environmental Precautions:** Contain material and prevent release to waterways or soil.

## **6.3. Methods and material for containment and cleaning up**

**Methods for Cleaning Up:** Recover product and place in an appropriate container for disposal.

## **6.4. Reference to other sections**

Refer to Sections 8, 12, and 13 for further information.

# **Section 7. Handling and storage**

## **7.1. Precautions for safe handling**

Handle in accordance with good industrial hygiene and safety practice.

## **7.2. Conditions for safe storage, including any incompatibilities**

Store according to label instructions.

## **7.3. Specific end use(s)**

**Recommended use:** Pharmaceuticals

# **Section 8. Exposure controls/personal protection**

## **8.1. Control parameters**

### **Exposure limits:**

<b>Chemical Name</b>	<b>Employee Exposure Limit</b>	<b>Skin Notation</b>
Sodium Hydrogen Divalproate 76584-70-8	160 mcg/m <sup>3</sup> as Valproic Acid	None
Talc, Nonasbestos Containing 14807-96-6	Not Applicable	None
Silica, Amorphous 112926-00-8	Not Applicable	None
Cellulose Microcrystalline 9004-34-6	Not Applicable	None

**Product Name:** Depakene Coated Tablets  
**Issued:** Jun-01-2015

Cellacefat 9004-38-0	Not Applicable	None
Kollidon 9003-39-8	Not Applicable	None
Dibutyl Phthalate 84-74-2	Not Applicable	None
Titanium Dioxide 13463-67-7	Not Applicable	None

Chemical Name	ACGIH TLV	France	German MAK	Ireland	Italy
Talc, Nonasbestos Containing 14807-96-6	2 mg/m <sup>3</sup> TWA			10 mg/m <sup>3</sup> (TWA) 0.8 mg/m <sup>3</sup> (TWA)	
Silica, Amorphous 112926-00-8	10 mg/m <sup>3</sup>				
Cellulose Microcrystalline 9004-34-6	10 mg/m <sup>3</sup> TWA	TWA: 10 mg/m <sup>3</sup>		20 mg/m <sup>3</sup> (STEL) 10 mg/m <sup>3</sup> (TWA) 4 mg/m <sup>3</sup> (TWA)	5.00 mg/m <sup>3</sup> (TWA)
Kollidon 9003-39-8	10 mg/m <sup>3</sup> for nuisance dust; 3 mg/m <sup>3</sup> respirable particulate				
Dibutyl Phthalate 84-74-2	5 mg/m <sup>3</sup> TWA	TWA: 5 mg/m <sup>3</sup>	0.1 ppm Peak 1.16 mg/m <sup>3</sup> Peak	10 mg/m <sup>3</sup> (STEL) 5 mg/m <sup>3</sup> (TWA)	
Titanium Dioxide 13463-67-7	10 mg/m <sup>3</sup> TWA	TWA: 10 mg/m <sup>3</sup>		10 mg/m <sup>3</sup> (TWA) 4 mg/m <sup>3</sup> (TWA)	

Chemical Name	The Netherlands	Spain	Switzerland	UK OEL/MEL
Talc, Nonasbestos Containing 14807-96-6	0.25 mg/m <sup>3</sup> (TWA)	2 mg/m <sup>3</sup> (TWA)	2 mg/m <sup>3</sup> (TWA)	3 mg/m <sup>3</sup> (STEL) 1 mg/m <sup>3</sup> (TWA)
Silica, Amorphous 112926-00-8			4 mg/m <sup>3</sup> (TWA)	
Cellulose Microcrystalline 9004-34-6		10 mg/m <sup>3</sup> (TWA)	3 mg/m <sup>3</sup> (TWA)	20 mg/m <sup>3</sup> (STEL) 12 mg/m <sup>3</sup> (STEL) 10 mg/m <sup>3</sup> (TWA) 4 mg/m <sup>3</sup> (TWA)
Dibutyl Phthalate 84-74-2		5 mg/m <sup>3</sup> (TWA)	0.05 ppm (TWA) 0.58 mg/m <sup>3</sup> (TWA) 0.1 ppm (STEL) 1.16 mg/m <sup>3</sup> (STEL)	10 mg/m <sup>3</sup> (STEL) 5 mg/m <sup>3</sup> (TWA)
Titanium Dioxide 13463-67-7		10 mg/m <sup>3</sup> (TWA)	3 mg/m <sup>3</sup> (TWA)	30 mg/m <sup>3</sup> (STEL) 12 mg/m <sup>3</sup> (STEL) 10 mg/m <sup>3</sup> (TWA) 4 mg/m <sup>3</sup> (TWA)

## 8.2. Exposure controls

### Engineering Controls:

No special provisions are required under normal product use conditions. When handling bulk formulation, use in a well-ventilated area.

### Respiratory Protection:

Respiratory protection is not needed during normal product use. When handling the bulk formulation, an approved respirator (i.e. NIOSH, EN, etc.) should be worn when exposures are expected to exceed the applicable limits.

### Eyes:

Eye protection not needed during typical product use conditions. Wear eye protection as appropriate when handling the bulk formulation.

### Gloves:

Gloves not required during normal product use conditions. Wear impervious gloves when handling the bulk formulation.

### Other PPE Data:

Wear appropriate body coverings if contact may occur.

### Environmental Exposure Controls:

Not determined

## Section 9. Physical and chemical properties

**Product Name:** Depakene Coated Tablets  
**Issued:** Jun-01-2015

### **9.1. Information on basic physical and chemical properties**

<b>Appearance:</b>	Tablet
<b>Odor:</b>	Characteristic odor
<b>Odor Threshold:</b>	Not determined
<b>pH:</b>	Not determined.
<b>Boiling Pt. @ 760 mm Hg (°C):</b>	Not determined.
<b>Melting/Freezing Point (°C):</b>	Not determined
<b>Flash Point (°C):</b>	Not determined.
<b>Evaporation Rate at 20°C:</b>	Not determined.
<b>Flammability (Solid):</b>	Not determined.
<b>Lower Explosive Limit:</b>	Not determined.
<b>Upper Explosive Limit:</b>	Not determined.
<b>Vapor Pressure (mm Hg):</b>	Not determined.
<b>Vapor Density (Air = 1):</b>	Not determined.
<b>Specific Gravity:</b>	Not determined.
<b>Solubility(ies):</b>	Not determined.
<b>Partition coefficient:</b>	Not determined.
<b>n-octanol/water</b>	
<b>Autoignition Temp. (°C):</b>	Not determined.
<b>Decomposition temperature (°C):</b>	Not determined.
<b>Viscosity (centipoise):</b>	Not determined.
<b>Explosion Severity:</b>	Not determined.
<b>Oxidizer Properties:</b>	Not determined.

### **9.2. Other information**

Not determined

## **Section 10. Stability and reactivity**

### **10.1. Reactivity**

Not determined

### **10.2. Chemical stability**

Stable under normal conditions

### **10.3. Possibility of hazardous reactions**

**Hazardous reactions:** Not determined.

### **10.4. Conditions to avoid**

Not determined.

### **10.5 Incompatible materials**

Not determined

### **10.6 Hazardous decomposition products**

Carbon oxides, Nitrogen oxides (NO<sub>x</sub>)

**Product Name:** Depakene Coated Tablets  
**Issued:** Jun-01-2015

## Section 11. Toxicological information

### 11.1. Information on toxicological effects

#### Routes of Exposure:

**Oral:** Clinical Route  
**Dermal:** Not determined.  
**Inhalation:** Not determined.

**Acute Toxicity - Oral:** Data for component (s) given below.

Chemical Name	Acute Test	Value	Units	Species
Sodium Hydrogen Divalproate 76584-70-8	LD50 =	2060	mg/kg	Mice
	LD50 =	2710 .	mg/kg	Rats
Cellulose Microcrystalline 9004-34-6	LD50 >	5000	mg/kg	Rats
Kollidon 9003-39-8	LD50 =	100000	mg/kg	Rats
	LD50 >	1040 40000		Rabbits Mice
Dibutyl Phthalate 84-74-2	LD50 =	7499	mg/kg	Rats
		3474		Mice

**Acute Toxicity - Dermal:** Data for component (s) given below.

Chemical Name	Acute Test	Value	Units	Species
Cellulose Microcrystalline 9004-34-6	LD50 >	2000	mg/kg	Rabbits
Dibutyl Phthalate 84-74-2	LD50 >	20	ml/kg	Rabbits

**Acute Toxicity - Inhalation:** Data for component (s) given below.

Chemical Name	Test	Value	Units	Species	
Cellulose Microcrystalline 9004-34-6	LC 50 >	5800	mg/m³ , 4 hour	Rats	
Dibutyl Phthalate 84-74-2	LC 50 =	4250 25,000	mg/m³	Rats Mice	
Chemical Name	Test Type	Value	Units	Species	Comments
Dibutyl Phthalate 84-74-2	LD50 (iv) =	720	mg/kg	Mice	

**Corrosivity:** Not determined.

**Dermal Irritation:** Active Ingredient : Produced mild to moderate skin irritation in animals.

**Eye Irritation:** Active Ingredient : Produced severe eye irritation in animals. Recovery after 24 hours.

**Sensitization:** Not determined.

**Toxicokinetics/Metabolism:** Not determined.

**Target Organ Effects:** Data for component (s) given below.

Chemical Name	Target Organs:	Species	Dosage	Units	Route	Duration
Titanium Dioxide 13463-67-7	Lungs	Rats	10,000	mg/L	Inhalation	2 years

**Product Name:** Depakene Coated Tablets  
**Issued:** Jun-01-2015

**Reproductive Effects:** No effect anticipated from intact clinical product. Active Ingredient : In animals adverse reproductive effects include: testicular atrophy, reduced sperm count, fetal abnormalities. fetal toxicity.  
 In humans adverse reproductive effects include: fetal abnormalities.  
 Data for component (s) given below.

Chemical Name	Species	Dosage	Units	Route	Duration
Sodium Hydrogen Divalproate 76584-70-8	Rats Mice Rabbits	> 65	mg/kg	Oral	During Gestation

**Carcinogenicity:** None expected from normal clinical use of this product. Confirmed animal carcinogen with unknown relevance to humans  
 Data for component(s) given below.

Chemical Name	Site of Tumors	Species	Dosage	Route	Units	Duration
Sodium Hydrogen Divalproate 76584-70-8	Lungs Liver	Rats	80 - 170	Not Specified	mg/kg	2 years
Talc, Nonasbestos Containing 14807-96-6	Lungs	Rats	18	Inhalation	mg/m <sup>3</sup> , 6 hours	2 years
Titanium Dioxide 13463-67-7	Lungs	Rats	250,000	Inhalation	mg/L	2 years

**Mutagenicity:** Active Ingredient : Negative in mutagenicity assays.

**Aspiration hazard:** Not determined

**Notes:**

1. ALD: Approximate lethal dosage
2. LC50: Concentration in air that produces 50% mortality
3. LD50: Oral or dermal dosage that produces 50% mortality

## Section 12. Ecological information

### 12.1. Toxicity

Not determined.

Chemical Name	Percent	LC 50 (mg/l)	Species	Duration
Dibutyl Phthalate 84-74-2	1-10	1.3 0.73	Fathead Minnow Bluegill	96 Hours

Chemical Name	Percent	48h EC50 (daphnia - mg/l) (48HLCD)	Species	Duration
Dibutyl Phthalate 84-74-2	1-10	3.4	Daphnia magna	48 Hours

Chemical Name	Percent	72h IC50 (algae - mg/l) (72HICA)	Species	Duration
Dibutyl Phthalate 84-74-2	1-10	1.2 3.5	Desmodesmus subspicatus	72 Hours 48 Hours

### 12.2. Persistence and degradability

Not determined.

Chemical Name	Percent	% Degradation	Duration
Dibutyl Phthalate 84-74-2	1-10	81	28 days

### 12.3. Bioaccumulative potential

Not determined



**Product Name:** Depakene Coated Tablets  
**Issued:** Jun-01-2015

#### **12.4. Mobility in soil**

Not determined.

#### **12.5. Results of PBT or vPvB assessment**

Chemical safety report is not required for this substance/product.

#### **12.6. Other adverse effects**

Do not allow undiluted material or large quantities to reach groundwater, bodies of water or sewer system.

#### **Notes:**

1. EC50: Concentration in water that produces 50% mortality in *Daphnia* sp.
2. LC50: Concentration in water that produces 50% mortality in fish.
3. EbC50/ErC50: Concentration in water that produces 50% inhibition of growth and in algae.

### **Section 13. Disposal considerations**

#### **13.1 Waste treatment methods**

**Waste Disposal Methods:** Disposal should be made in accordance with country, federal, state and local regulations.

### **Section 14. Transport information**

#### **ADR, DOT, ICAO/IATA, IMDG/IMO**

**Status:** Not regulated

**14.1. UN Number:** Not applicable  
**14.2. Proper shipping name:** Not applicable  
**14.3. Hazard class:** Not applicable  
**14.4. Packing group:** Not applicable  
**14.5. Environmental hazard:** Not applicable  
**14.6. Special Provisions:** Not applicable  
**14.7. Transport in bulk** Not applicable  
**according to Annex II of**  
**MARPOL 73/78 and the IBC**  
**Code:**

### **Section 15. Regulatory Information**

#### **15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture**

#### **International Inventories**

Chemical Name	EINECS/ ELINCS	TSCA	DSL	NDSL	PICCS
Sodium Hydrogen Divalproate 76584-70-8	-	-	-	Not listed.	-
Talc, Nonasbestos Containing 14807-96-6	Present	X	X	Not listed.	X
Silica, Amorphous 112926-00-8	-	-	X	Not listed.	X
Cellulose Microcrystalline 9004-34-6	Present	X	X	Not listed.	X

**Product Name:** Depakene Coated Tablets  
**Issued:** Jun-01-2015

Cellacefate 9004-38-0	-	X	X	Not listed.	X
Kollidon 9003-39-8	-	X	X	Not listed.	X
Dibutyl Phthalate 84-74-2	Present	X	X	Not listed.	X
Titanium Dioxide 13463-67-7	Present	X	X	Not listed.	X

Chemical Name	ENCS	ISHL	IECSC	AICS	KECL	New Zealand
Sodium Hydrogen Divalproate 76584-70-8	Present	Present	-	-	-	
Talc, Nonasbestos Containing 14807-96-6	Present	-	X	X	Present	
Silica, Amorphous 112926-00-8	Present	-	X	X	Present	
Cellulose Microcrystalline 9004-34-6	Present	-	X	X	Present	
Cellacefate 9004-38-0	Present	-	X	X	-	
Kollidon 9003-39-8	Present	-	X	X	Present	
Dibutyl Phthalate 84-74-2	Present	-	X	X	Present	HSR002713
Titanium Dioxide 13463-67-7	Present	-	X	X	Present	

### Legend

**EINECS/ELINCS** - European Inventory of Existing Commercial Chemical Substances/EU List of Notified Chemical Substances

**TSCA** - United States Toxic Substances Control Act Section 8(b) Inventory

**DSL/NDSL** - Canadian Domestic Substances List/Non-Domestic Substances List

**PICCS** - Philippines Inventory of Chemicals and Chemical Substances

**ENCS** - Japan Existing and New Chemical Substances

**ISHL** - Japan Industrial Safety and Health Law

**IECSC** - China Inventory of Existing Chemical Substances

**AICS** - Australian Inventory of Chemical Substances

**KECL** - Korean Existing and Evaluated Chemical Substances

### Carcinogenicity Rating:

Chemical Name	Percent	NTP:	IARC:	ACGIH:
Sodium Hydrogen Divalproate	50-70	Not Listed	Not Listed	Not Listed
Talc, Nonasbestos Containing	5-20	Not Listed	Not Listed	Not Listed
Silica, Amorphous	1-10	Not Listed	Not Listed	Not Listed
Cellulose Microcrystalline	1-10	Not Listed	Not Listed	Not Listed
Cellacefate	1-10	Not Listed	Not Listed	Not Listed
Kollidon	1-10	Not Listed	Not Listed	Not Listed
Dibutyl Phthalate	1-10	Not Listed	Not Listed	Not Listed
Titanium Dioxide	0.1-1	Not Listed	Not Listed	Not Listed

### SARA 313 Information

Chemical Name	Percent	SARA 313 Chemical:	CERCLA RQ/SARA EHS RQ (lbs):	SARA EHS TPQ (lbs):
Sodium Hydrogen Divalproate	50-70	No	Not Applicable	Not applicable
Talc, Nonasbestos Containing	5-20	No	Not Applicable	Not applicable
Silica, Amorphous	1-10	No	Not Applicable	Not applicable
Cellulose Microcrystalline	1-10	No	Not Applicable	Not applicable
Cellacefate	1-10	No	Not Applicable	Not applicable
Kollidon	1-10	No	Not Applicable	Not applicable
Dibutyl Phthalate	1-10	No	Not Applicable	Not applicable
Titanium Dioxide	0.1-1	No	Not Applicable	Not applicable

**Immediate Health:** Yes

**Delayed Health:** No

**Fire:** No

**Sudden Pressure:** No

**Product Name:** Depakene Coated Tablets  
**Issued:** Jun-01-2015  
**Reactivity:** No  
**RCRA Status:** Not determined.  
**Proposition 65 Status:** Chemicals known to the State of California to cause cancer or reproductive harm listed below.

Component	Percent	Proposition 65 Listed Materials
Sodium Hydrogen Divalproate 76584-70-8 ( 50-70 )	50-70	Listed
Dibutyl Phthalate 84-74-2 ( 1-10 )	1-10	developmental toxicity, initial date 12/2/05 male reproductive toxicity, initial date 12/2/05 female reproductive toxicity, initial date 12/2/05

**WHMIS Hazard Class:** Not determined.

**NFPA Rating:**

Health: 2

Fire: 1

Reactivity: 0

**Notes:**

1. SARA = Superfund Amendments and the Reauthorization Act.
2. CERCLA = Comprehensive Environmental Response, Compensation and Liability Act.
3. FIFRA = Federal Insecticide, Fungicide and Rodenticide Act.
4. TSCA = Toxic Substances Control Act.
5. EC = European Community.
6. WHMIS = Canadian Workplace Hazardous Materials Information System.
7. UN GHS = United Nations Globally Harmonized System for Hazard Identification.

**15.2. Chemical safety assessment**

Chemical safety assessment has not been conducted on the substance/product.

**Section 16. Other information**

**Risk Phrases:**

R22 - Harmful if swallowed

R36/38 - Irritating to eyes and skin

R61 - May cause harm to the unborn child

R62 - Possible risk of impaired fertility

**Full text of H-Statements referred to under sections 2 and 3**

H315 - Causes skin irritation

H319 - Causes serious eye irritation

H302 - Harmful if swallowed

H400 - Very toxic to aquatic life

H360Df - May damage the unborn child. Suspected of damaging fertility

**Document Authored By:** Global Occupational Toxicology (D-03QC)

**Issued:** Jun-01-2015

**Supersedes the SDS dated:** Sep-05-2011

**Product Name:**

**Depakene Coated Tablets**

**Issued:**

**Jun-01-2015**

**Disclaimer:**

*The information and recommendations contained herein are based upon tests believed to be reliable. However, AbbVie Inc. does not guarantee their accuracy or completeness NOR SHALL ANY OF THIS INFORMATION CONSTITUTE A WARRANTY, WHETHER EXPRESSED OR IMPLIED, AS TO THE SAFETY OF THE GOODS, THE MERCHANTABILITY OF THE GOODS, OR THE FITNESS OF THE GOODS FOR A PARTICULAR PURPOSE. Adjustment to conform to actual conditions of usage may be required. AbbVie Inc. assumes no responsibility for results obtained or for incidental or consequential damages, including lost profits, arising from the use of these data. No warranty against infringement of any patent, copyright or trademark is made or implied.*